#NACFC2021 – Orkambi, Symdeko May Improve Children’s Liver Health

#NACFC2021 – Orkambi, Symdeko May Improve Children’s Liver Health

311171

#NACFC2021 – Orkambi, Symdeko May Improve Children’s Liver Health

Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis (CF) who have liver involvement, new data indicate. “We detected improvements in validated noninvasive biomarkers of liver fibrosis [scarring] and cirrhosis in children and adolescents treated with” these therapies, the researchers wrote in a poster presented at the 2021 North American Cystic Fibrosis Conference (NACFC), being held virtually Nov. 2–5. The research findings were discussed in a…

You must be logged in to read/download the full post.